Portfolio Evermount Capital Management focuses on discovering and buying out companies with
sustainable competitiveness among Korean mid-market companies in growth stage.

Scroll

Portfolio

  • VAIM Bio, Healthcare

    Korea's leading biopharmaceutical company;

    Year : 2023 Status: Current
  • VAIM Bio, Healthcare

    Korea's leading biopharmaceutical company; acquired a 66.7% of stake in Aug 2021

    Year : 2021 Status: Exited